Fasting Insulin
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- Fasting insulin is the earliest marker of insulin resistance — it rises years before fasting glucose or HbA1c become abnormal, making it the most sensitive early warning signal available.
- It is not included in standard metabolic panels. Most people have never had fasting insulin measured despite it being one of the most important metabolic biomarkers. You must specifically request it.
- Longevity-optimal target: below 6 µIU/mL. Standard labs flag anything below 25 µIU/mL as normal — a range so wide it misses significant metabolic dysfunction at values of 10–20 µIU/mL.
- Chronically elevated insulin is a potent aging accelerator — independent of glucose levels. High insulin promotes cellular proliferation, suppresses autophagy, drives inflammation, and is associated with cardiovascular disease and cancer risk.
- Always pair with HbA1c and fasting glucose. Normal glucose with high insulin means the pancreas is overworking to compensate — this is the window where intervention is most effective and most often missed.
Why Fasting Insulin Is the Most Important Metabolic Marker Most People Have Never Tested
If you have had routine blood work at any point in your life, the chances are excellent that your doctor checked your fasting glucose and perhaps your HbA1c. The chances are much lower that fasting insulin was ever measured — despite it being a more sensitive, more actionable, and arguably more important marker for metabolic health and longevity.
The reason comes down to how the current medical system defines metabolic disease. Diabetes and prediabetes are defined by elevated glucose. Insulin resistance — the underlying dysfunction that drives glucose dysregulation — is not a clinical diagnosis but a physiological state, and fasting insulin is its most direct accessible measure. Because insulin resistance doesn't have its own ICD billing code and because standard metabolic screening focuses on glucose, millions of people spend years or decades in progressive metabolic dysfunction that is completely invisible to their annual bloodwork.
By the time fasting glucose rises above 100 mg/dL or HbA1c climbs above 5.4%, insulin resistance has typically been present for five to fifteen years. During that entire window, fasting insulin was elevated — and could have been detected with a single additional test costing $25–35. The failure to include fasting insulin in standard metabolic panels is one of the more consequential gaps in conventional preventive medicine.
How Insulin Resistance Develops: The Compensation Cascade
Insulin resistance does not develop overnight, and it does not announce itself. It unfolds through a slow, decades-long compensation cascade that is silent by design — until it isn't.
In a metabolically healthy person, cells throughout the body — particularly in skeletal muscle, liver, and adipose tissue — respond efficiently to insulin. When a meal raises blood glucose, the pancreatic beta cells secrete a modest amount of insulin; cells take up the glucose promptly; blood glucose returns to baseline; and insulin levels fall back to their low fasting level. The system is sensitive, responsive, and requires little insulin to work well.
Insulin resistance begins when cells start responding less efficiently to insulin's signal. The most common cause is chronic caloric surplus — particularly from refined carbohydrates and fructose — combined with physical inactivity. As cells become overfull and chronically exposed to high insulin levels, they downregulate their insulin receptor density and impair downstream insulin signaling. Glucose uptake slows. Blood glucose threatens to rise after meals.
The pancreas responds by secreting more insulin. And this compensation works — remarkably well, for a remarkably long time. Blood glucose remains normal. HbA1c remains normal. The standard metabolic panel shows nothing unusual. But insulin is running at three, five, or ten times its optimal level to achieve the same glucose control that a small fraction of that insulin could achieve in a healthy cell.
This is the stage that fasting insulin reveals. And this is the stage when intervention is most effective — before the pancreas's compensatory capacity is exhausted, before glucose rises, before years of high-insulin tissue damage have accumulated.
Standard Reference Ranges vs. Longevity-Optimal Ranges
The standard reference range for fasting insulin — typically 2–25 µIU/mL — is calibrated to detect overt hyperinsulinemia and frank insulin resistance at the severe end. It says nothing useful about metabolic optimization. Someone with fasting insulin of 22 µIU/mL is technically "normal" by this range, yet is likely deeply insulin resistant with significantly elevated metabolic disease risk.
| Fasting Insulin (µIU/mL) | Standard Interpretation | Longevity Assessment |
|---|---|---|
| 2–6 | Normal | Optimal — excellent insulin sensitivity |
| 7–10 | Normal | Early resistance — worth addressing proactively |
| 11–15 | Normal | Meaningful resistance — lifestyle intervention indicated |
| 16–24 | Normal | Significant resistance — aggressive intervention needed |
| 25+ | Borderline/High | Severe resistance — clinical evaluation warranted |
The HOMA-IR score — Homeostatic Model Assessment of Insulin Resistance — provides a more complete picture by combining fasting insulin and fasting glucose: HOMA-IR = (fasting insulin × fasting glucose) / 405 (when glucose is in mg/dL). A HOMA-IR below 1.0 reflects excellent insulin sensitivity. Values above 1.9 indicate early insulin resistance, and values above 2.9 indicate significant resistance. Calculating HOMA-IR alongside absolute fasting insulin gives the most actionable interpretation.
Already have your lab results? See how your fasting insulin and other markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →The Independent Harms of Chronically Elevated Insulin
Chronically high insulin is not merely a marker of metabolic dysfunction — it is an active driver of aging and disease through several distinct mechanisms. Even in people where the pancreas can sustain the compensation indefinitely and glucose never rises, the insulin itself is causing damage.
Cardiovascular disease: Insulin promotes smooth muscle cell proliferation in arterial walls, stimulates sympathetic nervous system activity (raising blood pressure), impairs endothelial nitric oxide production, and drives dyslipidemia — specifically raising triglycerides and lowering HDL cholesterol, the classic lipid pattern of insulin resistance. These effects are independent of glucose levels. People with hyperinsulinemia have significantly elevated cardiovascular risk even with normal blood glucose, and this risk is often invisible to cholesterol-focused risk calculators that don't account for insulin.
Cancer: Insulin is a potent growth factor. It activates many of the same proliferative signaling pathways as IGF-1 — promoting cell division, inhibiting apoptosis, and supporting tumor cell survival and growth. Epidemiological studies consistently link hyperinsulinemia to elevated risk of breast, colorectal, pancreatic, and endometrial cancer, independent of obesity and diabetes status. The association is not merely correlational — insulin receptors are overexpressed in many tumor types, and tumor cells actively exploit the high-insulin environment.
Neurodegeneration: The brain is an insulin-sensitive organ, and brain insulin resistance — sometimes called "type 3 diabetes" — impairs the clearance of amyloid beta peptides and tau proteins, the pathological hallmarks of Alzheimer's disease. Chronic hyperinsulinemia drives competition between insulin and amyloid beta for the insulin-degrading enzyme that clears both, potentially accelerating amyloid accumulation. Longitudinal studies find that midlife hyperinsulinemia is a significant independent predictor of late-life dementia.
mTOR activation and suppressed autophagy: Insulin is one of the primary activators of mTOR — the cellular growth and energy sensor that, when chronically activated, suppresses autophagy (cellular self-cleaning) and promotes cellular senescence. The longevity benefits of caloric restriction and fasting in model organisms are mediated in significant part through mTOR inhibition driven by lower insulin levels. Chronic hyperinsulinemia keeps mTOR chronically active, accelerating the cellular aging processes it governs.
Hormonal disruption: Elevated insulin increases the activity of an enzyme called aromatase, which converts androgens to estrogens — contributing to estrogen dominance in women and testosterone suppression in men. In women with polycystic ovary syndrome (PCOS), insulin resistance is the central pathophysiological driver. In men, hyperinsulinemia is associated with lower testosterone and higher estradiol, directly impairing body composition and metabolic health in a reinforcing feedback loop.
What Drives Fasting Insulin Up — and How to Bring It Down
Fasting insulin is among the most responsive biomarkers to lifestyle intervention. Meaningful reductions are achievable in weeks with consistent changes — not months or years.
Primary drivers of elevated fasting insulin
- High refined carbohydrate and sugar intake: Frequent spikes in blood glucose from ultra-processed foods, sugar-sweetened beverages, and refined starches drive repeated high-insulin secretion, progressively impairing insulin receptor sensitivity. This is the primary dietary driver.
- Physical inactivity: Skeletal muscle is the largest site of insulin-stimulated glucose disposal. Inactive muscle has reduced GLUT4 transporter expression and reduced glycogen storage capacity — meaning more insulin is required to clear any given glucose load.
- Visceral adiposity: Visceral fat (fat stored around the abdominal organs) secretes inflammatory cytokines that directly impair insulin signaling in muscle and liver. It also releases free fatty acids that compete with glucose for uptake and impair insulin action. The waist-to-height ratio is a useful proxy for visceral fat load.
- Chronic sleep deprivation: Even a single week of sleeping 5–6 hours instead of 7–9 hours significantly reduces insulin sensitivity in healthy adults. Chronic sleep restriction is a major and underappreciated driver of insulin resistance.
- Chronic psychological stress: Cortisol directly antagonizes insulin action, reduces GLUT4 expression, and promotes hepatic glucose output. Chronically elevated cortisol from psychological stress is a meaningful contributor to insulin resistance independent of diet.
- Fructose overconsumption: Dietary fructose — primarily from added sugars and high-fructose corn syrup — is metabolized almost entirely in the liver, where it drives de novo lipogenesis (fat synthesis), hepatic insulin resistance, and triglyceride elevation. High fructose intake is disproportionately damaging to metabolic health relative to its caloric contribution.
Most effective interventions to lower fasting insulin
- Reducing refined carbohydrates: Lowering dietary glycemic load is the most direct intervention. This does not require a ketogenic diet — reducing sugar-sweetened beverages, processed snack foods, refined grains, and desserts while maintaining whole-food carbohydrate sources (legumes, vegetables, intact whole grains) is sufficient for most people to see meaningful improvement within 4–8 weeks.
- Resistance training: Heavy compound exercise acutely increases GLUT4 expression in muscle cells and improves insulin-stimulated glucose uptake for 24–72 hours after each session. With consistent training, these effects become permanent structural adaptations. Even 2–3 sessions per week produces clinically meaningful insulin sensitization.
- Post-meal walking: A 10–20 minute walk after meals blunts postprandial glucose spikes by directing glucose into contracting muscle without requiring insulin — reducing the total insulin secreted in response to each meal. Over time this reduces the insulin burden on the pancreas and improves sensitivity.
- Time-restricted eating: Compressing caloric intake into an 8–10 hour window (with a consistent overnight fast of 14–16 hours) reliably lowers fasting insulin in most people, likely through a combination of reduced total carbohydrate intake and enhanced insulin sensitivity during the fasting period.
- Reducing visceral fat: Any intervention that reduces abdominal fat — whether through caloric deficit, resistance training, or improved sleep — reduces the inflammatory and lipolytic signals that impair insulin receptor function in muscle and liver.
- Improving sleep: Restoring 7–9 hours of quality sleep in chronically sleep-deprived individuals improves insulin sensitivity within days to weeks.
How to Test Fasting Insulin
Fasting insulin requires a blood draw after at least 8–10 hours of fasting — no food, no caloric beverages, and ideally no significant exercise in the preceding 24 hours (which can transiently lower fasting insulin). Water and non-caloric beverages are fine.
Always order fasting insulin alongside fasting glucose and HbA1c. These three markers together tell the complete metabolic story: fasting glucose captures the current glucose environment, HbA1c captures the 90-day average, and fasting insulin reveals the degree of pancreatic compensation required to maintain that glucose level. A high fasting insulin with normal glucose is a clear signal of compensated insulin resistance — the most actionable finding.
Calculating HOMA-IR from your fasting insulin and fasting glucose adds additional interpretive value and allows tracking of insulin sensitivity over time as a single number. The formula: (fasting insulin in µIU/mL × fasting glucose in mg/dL) ÷ 405.
For most adults, annual testing as part of a comprehensive metabolic panel is appropriate. If fasting insulin is elevated and you are actively implementing lifestyle changes, retesting at 60–90 days captures the impact of interventions within a reasonable timeframe. Fasting insulin can respond rapidly — some people see 30–40% reductions within 4–6 weeks of meaningful dietary change.
Sources
- Festa A, et al. "Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)." Circulation, 2000. PubMed →
- Despres JP, Lamarche B. "Effects of Diet and Physical Activity on Adiposity and Body Fat Distribution: Implications for the Prevention of Cardiovascular Disease." Nutrition Research Reviews, 1993. PubMed →
- Craft S. "The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia." Archives of Neurology, 2009. PubMed →
| Range Type | Value (µIU/mL) | Notes |
|---|---|---|
| Standard Clinical Range | 2–25 µIU/mL (varies by lab) | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | 2–6 µIU/mL |
Associated with reduced all-cause mortality and extended healthspan.
Standard reference ranges extend to 25 µIU/mL — a threshold calibrated to catch overt hyperinsulinemia, not to optimize metabolic health. Population studies and longevity medicine consensus target fasting insulin below 6 µIU/mL as optimal, with values of 8–12 suggesting early insulin resistance worth addressing and values above 12–15 indicating meaningful dysfunction.
|
Already have your results? See what your Fasting Insulin and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
What is the optimal fasting insulin level?
The longevity medicine community targets fasting insulin below 6 µIU/mL. Values of 2–6 µIU/mL reflect excellent insulin sensitivity — the pancreas is producing only the small amount needed to maintain baseline glucose control, and cells are responding efficiently to insulin's signals. Values of 7–10 µIU/mL suggest early, subclinical insulin resistance worth addressing through lifestyle. Values above 12–15 µIU/mL indicate meaningful insulin resistance, and values above 20 µIU/mL represent significant dysfunction even if glucose and HbA1c remain technically normal. Standard labs set the upper limit of normal at 20–25 µIU/mL — a threshold calibrated to detect overt disease, not to optimize metabolic health.
Why isn't fasting insulin included in standard blood panels?
Fasting insulin is not part of standard metabolic screening for a combination of historical, economic, and clinical inertia reasons. When the current paradigm for metabolic disease screening was established, the focus was on detecting diabetes — and fasting glucose was sufficient for that purpose. Insulin resistance as a pre-diabetic condition was less well understood, and the concept of treating insulin resistance before glucose became abnormal was not part of standard medical practice. Additionally, insulin assays historically had significant variability between labs, which made establishing universal reference ranges difficult. Today, standardized high-quality assays are widely available, the clinical evidence for insulin resistance as an independent risk factor is robust, and there is no good clinical reason to omit fasting insulin from metabolic panels — but the standard of care has been slow to change.
Can fasting insulin be high if HbA1c and glucose look normal?
Yes — and this is precisely why fasting insulin is so valuable. During the early and middle stages of insulin resistance, the pancreas compensates by producing more and more insulin to keep blood glucose in the normal range. This compensation can be maintained for years or decades. During this entire period, glucose and HbA1c look normal on standard labs, and the person appears metabolically healthy by conventional screening criteria. Only fasting insulin reveals the underlying dysfunction — the pancreatic overwork that is silently accumulating metabolic damage. By the time HbA1c rises above 5.7%, insulin resistance has typically been present for many years. Catching it while insulin is high but glucose is still normal is the highest-leverage intervention point.
What are the symptoms of high fasting insulin?
Chronically elevated fasting insulin often produces no obvious symptoms in the early stages — which is part of what makes it dangerous. As insulin resistance progresses, common signs include difficulty losing weight despite reasonable diet and exercise, fat accumulation preferentially in the abdomen (visceral fat), energy crashes and hunger 2–3 hours after meals, intense carbohydrate cravings, afternoon energy slumps, skin tags (a dermatological marker of chronic hyperinsulinemia), dark patches of skin in body folds called acanthosis nigricans, elevated triglycerides with low HDL on lipid panels, and elevated blood pressure. Many of these signs are also features of metabolic syndrome — which is, at its root, a syndrome of insulin resistance.
How quickly can you lower fasting insulin?
Fasting insulin responds faster to lifestyle intervention than almost any other metabolic biomarker. In people with elevated fasting insulin but normal glucose, significant reductions — often 30–50% — can occur within 4–8 weeks of meaningful dietary and exercise changes. The most effective interventions are reducing refined carbohydrate and sugar intake (which directly reduces the insulin demand from each meal), adding resistance training (which increases muscle glucose uptake capacity and reduces the insulin required to clear any given carbohydrate load), and reducing visceral fat through any combination of the above. Time-restricted eating and intermittent fasting also effectively lower fasting insulin in most people, likely through a combination of reduced overall carbohydrate intake and enhanced insulin sensitivity from the fasting period itself.